Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469788 | 0.76 | ABCC9 (0.45) | L3MBTL1HDAC1ABCC9ABCC8KCNJ11 | |
| SCHEMBL2471576 | 0.65 | LTA4H (0.44) | SMN1; SMN2HDAC1ALDH1A1 | |
| SCHEMBL10252235 | 0.63 | L3MBTL1 (0.42) | L3MBTL1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL13363823 | 0.63 | L3MBTL1 (0.49) | L3MBTL1SMN1; SMN2FGFR3 | |
| SCHEMBL13336469 | 0.63 | MEN1 (0.66) | SMN1; SMN2ALDH1A1IDH2 | |
| SCHEMBL557514 | 0.62 | L3MBTL1 (0.67) | EPHX2L3MBTL1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5373645 | 0.61 | HPGD (0.54) | EPHX2SMN1; SMN2ALDH1A1 | |
| SCHEMBL14920514 | 0.61 | L3MBTL1 (0.47) | L3MBTL1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL238259 | 0.60 | LTA4H (0.73) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL9348376 | 0.60 | SMN1; SMN2 (0.53) | L3MBTL1SMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2175725-A1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009009015-A1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| EP-1858520-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | EPHX2 3184/4885L3MBTL1 3577/4885SMN1; SMN2 3218/4885 |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | EPHX2 3184/4885L3MBTL1 3577/4885SMN1; SMN2 3218/4885 |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | EPHX2 3184/4885L3MBTL1 3577/4885SMN1; SMN2 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.